Aoxing gains GMP certification from China's SFDA

27 April 2011

New York, USA-based specialty drug group Aoxing Pharmaceutical (NYSE Amex: AXN) said yesterday that its operating subsidiary in China, Hebei Aoxing Pharmaceutical, has received Good Manufacturing Practice (GMP) certification from the Chinese State Food and Drug Administration (SFDA) for the pre-treatment, extraction, tincture, and pill workshops, after a site inspection by SFDA.

The milestone marks the completion of the Lerentang Pharmaceutical Company's manufacturing facility relocation from Shijiazhuang to Xinle City, Hebei Province, the US firm noted. Aoxing Pharma has received government support for the relocation from Shijiazhuang City and Hebei Province, totaling $269,231 in the form of bank loan interest payment subsidies.

These facilities are expected to begin commercial production in mid-2011 and will enable Aoxing Pharma to supply all 11 of its licensed essential drugs to 29 provinces and municipalities in China (including military regions).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK